NCT01056601 arm group 42e328dabb1026de2ad2b2d75dca7f93 [clinicaltrials_resource:NCT01056601/arm-group/42e328dabb1026de2ad2b2d75dca7f93]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01056601 arm group 42e328dabb1026de2ad2b2d75dca7f93 [clinicaltrials_resource:NCT01056601/arm-group/42e328dabb1026de2ad2b2d75dca7f93]
Bio2RDF identifier
NCT01056601/arm-group/42e328dabb1026de2ad2b2d75dca7f93
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... e328dabb1026de2ad2b2d75dca7f93
description [clinicaltrials_vocabulary:description]
Pancreatic cancer patients who ...... er progressing on gemcitabine.
identifier
clinicaltrials_resource:NCT01056601/arm-group/42e328dabb1026de2ad2b2d75dca7f93
title
NCT01056601 arm group 42e328dabb1026de2ad2b2d75dca7f93
@en
type
label
NCT01056601 arm group 42e328da ...... 328dabb1026de2ad2b2d75dca7f93]
@en